Overview

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

Status:
Recruiting

Trial end date:
2025-11-01

Target enrollment:

Participant gender:

Summary

This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of Pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

NextCure, Inc.

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Pembrolizumab